|
|
|
|
LEADER |
02004 am a22002653u 4500 |
001 |
73627 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Doles, Jason D.
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
100 |
1 |
0 |
|a Doles, Jason D.
|e contributor
|
100 |
1 |
0 |
|a Hemann, Michael
|e contributor
|
700 |
1 |
0 |
|a Hemann, Michael
|e author
|
245 |
0 |
0 |
|a Nek4 Status Differentially Alters Sensitivity to Microtubule Poisons
|
246 |
3 |
3 |
|a Nek4 Status Differentially Alters Sensitivity to Distinct Microtubule Poisons
|
260 |
|
|
|b American Association for Cancer Research,
|c 2012-10-04T20:08:03Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/73627
|
520 |
|
|
|a 2011 February 1
|
520 |
|
|
|a Microtubule poisons are widely used in cancer treatment, but the factors determining the relative efficacy of different drugs in this class remain obscure. In this study, we identified the NIMA kinase Nek4 in a genetic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtubules. After Taxol treatment, Nek4 promoted microtubule outgrowth, whereas Nek4 deficiency impaired G2-M arrest and decreased formation of mitotic-like asters. In contrast, Nek4 deficiency sensitized cells to vincristine, which destabilizes microtubules. Therefore, Nek4 deficiency may either antagonize or agonize the effects of microtubule poisons, depending on how they affect microtubule polymerization. Of note, Nek4 gene maps to a commonly deleted locus in non-small cell lung cancer. Thus, Nek4 deletion in this disease may rationalize the use of particular types of microtubule poisons for lung cancer therapy.
|
520 |
|
|
|a Rita Allen Foundation (Fellow)
|
520 |
|
|
|a National Institutes of Health (U.S.) (Grant RO1 CA128803-01)
|
520 |
|
|
|a Massachusetts Institute of Technology. Dept. of Biology (Training Grant)
|
546 |
|
|
|a en_US
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Cancer Research
|